Agios Pharmaceuticals
AGIO
142 hedge funds and large institutions have $3.1B invested in Agios Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 50 funds opening new positions, 46 increasing their positions, 38 reducing their positions, and 24 closing their positions.
108% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 24
106% more capital invested
Capital invested by funds: $1.5B → $3.1B (+$1.6B)
21% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 38
18% more funds holding
Funds holding: 120 → 142 (+22)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
4% less call options, than puts
Call options by funds: $26.8M | Put options by funds: $28M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$176M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$76.5M |
| 3 |
CGT
Capital Guardian Trust
Los Angeles,
California
|
+$60.3M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$31.4M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$21.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$84.8M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$22M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$15.5M |
| 4 |
State Street
Boston,
Massachusetts
|
-$15.2M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$14.2M |
AGIO Hedge Fund Activity: Q4 2014 in Review
142 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q4 2014, worth a combined $3.1B — up 106% from $1.5B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new AGIO positions and 24 closed out — a net gain of 26 holders — while 46 added to existing stakes and 38 trimmed.
The largest buyer was Capital World Investors, adding an estimated $176M. The largest seller was Lord, Abbett & Co, cutting an estimated $84.8M.
- 142 institutional investors held Agios Pharmaceuticals (AGIO) as of Q4 2014, up from 120 in Q3 2014.
- Funds reported $3.1B of Agios Pharmaceuticals stock for Q4 2014, up 106% quarter-over-quarter.
- 50 funds opened new Agios Pharmaceuticals positions in Q4 2014 and 24 closed out, a net change of +26 holders.
- The largest Agios Pharmaceuticals buyer in Q4 2014 was Capital World Investors, an estimated $176M added.
- The largest Agios Pharmaceuticals seller in Q4 2014 was Lord, Abbett & Co, an estimated $84.8M sold.
Based on aggregated 13F filings for Q4 2014.